谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.
研究兴趣

论文共 73 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (pertuzumab Biosimilar) with Perjeta® in Patients with HER2-positive Metastatic Breast Cancer
Rushabh Kothari, Maulik Doshi, P. K. Chaithanya, C. T. Satheesh, Anil Kumar,Krishna Mohan Mallavarapu,Rajnish Nagarkar,Vijay Mahobia, Niraj Bhatt, K. L. Priyadarshini,Ajay Gogia,Tanveer Maksud, Saurabh Prasad, K. Velavan, L. K. Rajeev, S. S. Prakash,Vikas Talreja, Kaushal Kalra, Bhushan Nemade, Aloke Ghosh Dastidar, Tarachand Gupta, Tushar Patil, Shailesh Bondarde,Pinakin Patel,Sudeep Gupta,Ghanashyam Biswas, Manan Vaghela, Pinaki Mahato, Honey Parekh, Mahesh Kalloli, Rachan Shetty, Gaurav Prakash, Anil Goel, Srikrishna Mandal, Tamohan Choudhury,Minish Jain,Chanchal Goswami, H. M. Yathish Kumar, K. K. Mukherjee, Rahul Shrivastava, Deven Parmar
CLINICAL BREAST CANCERno. 7 (2024)
引用0浏览0WOS引用
0
0
Practical Consensus Guidelines on the Use of Cetuximab in Head and Neck Squamous Cell Carcinoma (HNSCC)
Purvish M. Parikh, Ghanashyam Biswas, Nilesh Ashok Dhamne, Chetan Dilip Deshmukh, Sewanti Limaye, Ashish Singh, Hemant Malhotra, Viashsta Pankaj Maniar, Bhupendra Nath Kapur, Prasad V. S. S. Sripada,Vikas Tulsidas Talreja, Poonam Patil, Suhas Vilasrao Agre, Amit Dilip Bhat, Priya Privadarshini Nayak, Arun Seshachalam, Boman Nariman Dhabhar, Ajay Sharma, Niraj N. Bhatt, Pratap Kishore Das, Atul Sharma, Govind Babu Kanakasetty, Suresh Hariram Advani
SOUTH ASIAN JOURNAL OF CANCER (2024)
引用0浏览0引用
0
0
Gestational Trophoblastic Disease
Seema Gulia,Vikas Talreja,Jaya Ghosh,Sudeep Gupta,Jyoti Bajpai
Tata Memorial Centre Textbook of Oncologypp.809-820, (2024)
引用0浏览0引用
0
0
加载更多
作者统计

#Papers: 74

#Citation: 661

H-Index: 13

G-Index: 25

Sociability: 5

Diversity: 2

Activity: 12

  • 合作者
  • 学生
  • 导师
暂无相似学者，你可以通过学者研究领域进行搜索筛选
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn